.png?sfvrsn=c3edc68e_6)
IMCB PROGRAMMES
IMCB is at the forefront of leading large, national-level programs that bring together expertise from researchers within IMCB and beyond, including collaborations with Institutes of Higher Learning (IHLs), medical centers, and other research institutions. These programs harness multi-disciplinary expertise across Singapore, to tackle critical national and global healthcare challenges in areas like cancer immunotherapy and cell-based therapies, driving impactful advancements in biomedical sciences and advancing health outcomes on both the national and global scale.
The PANAKEIA program focuses on developing advanced Natural Killer (NK) cell-based immunotherapies derived from induced pluripotent stem cells (iPSCs). By leveraging cutting-edge genome editing and cell differentiation technologies, PANAKEIA aims to create scalable, off-the-shelf NK cell therapies that address the limitations of current autologous approaches. These therapies are designed to be more accessible, consistent in quality, and tailored for targeting solid tumours and hematologic cancers.
The program integrates expertise across multiple disciplines, including cancer immunology, stem cell biology, and biomedical engineering, to engineer highly efficacious NK cell products. With a robust foundation in iPSC-derived cell technology, PANAKEIA aspires to transform cancer treatment by offering novel therapeutic assets that combine precision and scalability.
The SPECTRA program delves into the intricate processes of human thymus biology to pioneer the next generation of cell-based therapies. By utilizing state-of-the-art spatial multiomics technologies, the program seeks to map the molecular and cellular interactions that guide T cell development. This comprehensive approach offers unprecedented insights into the thymic microenvironment, paving the way for the creation of fully functional T cells derived from iPSCs.
SPECTRA brings together a multidisciplinary team with expertise in immunology, bioinformatics, and translational medicine. The program's findings hold the potential to revolutionise cell therapy, enabling the production of potent T cells for scalable applications that address global healthcare challenges.
A*STAR celebrates International Women's Day
From groundbreaking discoveries to cutting-edge research, our researchers are empowering the next generation of female science, technology, engineering and mathematics (STEM) leaders.